Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated by Analysts at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report sent to investors on Friday, Marketbeat reports. The brokerage issued an overweight rating and a $17.00 price target on the stock.

Other analysts have also issued research reports about the stock. Jefferies Financial Group assumed coverage on shares of Atyr PHARMA in a research report on Thursday, September 5th. They set a buy rating and a $9.00 target price on the stock. Royal Bank of Canada restated an outperform rating and set a $16.00 target price on shares of Atyr PHARMA in a research report on Wednesday, August 14th. Finally, HC Wainwright restated a buy rating and set a $35.00 target price on shares of Atyr PHARMA in a research report on Thursday, August 15th.

Atyr PHARMA Trading Up 7.5 %

Shares of Atyr PHARMA stock opened at $1.87 on Friday. Atyr PHARMA has a 12-month low of $1.08 and a 12-month high of $2.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.63 and a current ratio of 7.63. The stock has a market capitalization of $129.05 million, a PE ratio of -2.08 and a beta of 1.21. The firm has a 50-day moving average of $1.85.

Atyr PHARMA (NASDAQ:ATYR) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. On average, sell-side analysts forecast that Atyr PHARMA will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling at Atyr PHARMA

In related news, Director Paul Schimmel purchased 41,052 shares of the firm’s stock in a transaction on Monday, July 22nd. The shares were bought at an average price of $1.74 per share, for a total transaction of $71,430.48. Following the acquisition, the director now directly owns 354,075 shares in the company, valued at $616,090.50. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. 3.70% of the stock is owned by company insiders.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.